NOS2 and sarcoma: Given that L-NAME failed to improve the antitumor efficacy of the anti-PD-1 mAb in Nos2-deficient mice, and that L-NAME had some activity against distinct clones of Ifnar1-deficient sarcomas, we postulate that the functionally relevant source of NO is likely antigen presenting cells.